Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan
NCT04703322Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pexidartinib in tenosynovial giant cell tumor (TGCT), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2021; status: completed.
02
Drugs
pexidartinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NCT04703322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703322.